Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc., as a clinical-stage biopharmaceutical company, is advancing a promising cell therapy pipeline that includes autologous tumor infiltrating lymphocyte therapies and the innovative CoStAR platform for genetically engineered TIL therapies. The pipeline's lead candidate, ITIL-306, targets a tumor-associated antigen associated with several solid tumors, indicating significant market potential in oncology. Additionally, increasing validation of PD-(L)1 × VEGF activity and positive forthcoming updates in related clinical trials could contribute to a favorable market environment that reflects a strong outlook for Instil Bio’s stock performance.

Bears say

Instil Bio Inc faces a challenging outlook primarily due to concerns regarding the minimal improvements observed in overall survival (OS) curves, which have failed to impress investors and raise confidence in the company's clinical advancements. Additionally, the company is confronted with significant risks, including potential delays in progressing its candidates through clinical assessments, and a crucial need for favorable clinical data, particularly regarding AXN-2510 for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Furthermore, the threat of medium- to long-term dilution adds to investor anxiety, compounding concerns over the company’s financial stability and growth prospects.

Instil Bio (TIL) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Instil Bio (TIL) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.